# Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

> **NCT00943592** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 82 (actual)

## Conditions studied

- Advanced Hematologic Malignancies
- Leukemia
- Preleukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Melphalan
- **DRUG:** Campath
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00943592
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-04
- **Final completion:** 2013-11
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943592, "Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00943592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*